PubMed Health⌕ Search

PubMed · 6367976

Ergot, the "jerks," and revivals.

Abstract

Epidemics of epilepsy, a form of mass hysteria, were known in Eastern and Western cultures in the 17th and 18th centuries. A unique situation in the United States during the 19th centurey was the frontier religious movement, the setting in which the "jerks" occurred. The "falling exercise," "dancing exercise," "barking exercise," "laughing exercise," and the "running exercise" centered around the excitement involved in the religious revival. During some exercises, people saw "visions," and exhibited bizarre behavior and sudden jerking motions. During the summers of 1801-1803 on the Kentucky frontier, some pioneers who attended the religious revival camp meetings had convulsions, hallucinations, tremors, jerks, compulsive dancing and "epileptic trances." Although these have been assumed to be psychological in origin, the epidemiology of the symptoms may correlate with the diagnosis of ergotism. Those affected were usually children and young adults. Symptoms of ergotism include giddiness, fatigue, depression, formications, muscle twitching, tonic spasms, convulsions, delirium, and loss of speech.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J M Massey, E W Massey. 1984. Ergot, the "jerks," and revivals.. https://doi.org/10.1097/00002826-198403000-00006

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Long-term seizure outcomes and factors associated with response to adjunctive everolimus in TSC-associated epilepsy.

BACKGROUND: Everolimus, a mechanistic target of rapamycin (mTOR) inhibitor, is increasingly used in tuberous sclerosis complex (TSC)-associated epilepsy; however, long-term real-world outcomes and factors associated with favorable response remain unclear. This study aimed to evaluate the long-term seizure outcomes of adjunctive everolimus and explore clinical factors associated with treatment response. METHODS: We retrospectively recruited 21 patients with active TSC-associated epilepsy receiving adjunctive everolimus and assessed seizure outcomes during follow-up. Clinical characteristics were compared between responders and non-responders at 1 year after treatment initiation. RESULTS: Over a median treatment duration of 72 months, responder rates ranged from 53.8% to 64.7%, and seizure-free rates ranged from 33.3% to 41.2%. Responders had fewer involved organ systems at baseline (median 3 vs. 4, p = 0.020) and lower anti-seizure medication burden (median 2 vs. 4, p = 0.045). Younger age at treatment initiation showed a trend toward improved response. CONCLUSION: Adjunctive everolimus was associated with sustained long-term seizure reduction in this real-world cohort. In exploratory analyses, fewer involved organ systems and fewer baseline ASMs were associated with favorable treatment response. These findings require validation in larger prospective cohorts.

Epilepsy↗